LncRNA Information | ||||||
---|---|---|---|---|---|---|
ID | EL1171 | Name | RRP1B | Aliases | KIAA0179; NNP1L; Nnp1; PPP1R136; RRP1 | |
Species | Homo sapiens | Chromosome | 21 | Start site | 43659548 | |
End site | 43696079 | Chain | plus | Exon NO. | 16 | |
Assembly | Ensembl Release 89 | Class | retained intron | NCBI accession | N/A | |
Ensembl | ENSG00000160208 | Sequence | N/A |
Disease | |||||||||
---|---|---|---|---|---|---|---|---|---|
Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
cancer | N/A | N/A | N/A | epigenetics | RRP1B, a tumor progression and metastasis susceptibility candidate gene, is potentially a dynamic modulator of transcription and chromatin structure. | 19710015 | LncRNADisease | ||
Spinocerebellar ataxia type 7 | N/A | N/A | N/A | expression | CTCF is required for SCAANT1 expression. Loss of SCAANT1 derepressed ataxin-7 sense transcription in a cis-dependent fashion and was accompanied by chromatin remodeling. | 21689595 | LncRNADisease | ||
Spinocerebellar ataxia type 7 | N/A | N/A | N/A | mutation | For example, SCA7/ATXN7 antisense RNA 1 (SCAANT1) is an lncRNA transcribed antisense to the gene mutated in spinocerebellar ataxia type 7 (ATXN7), and it functions as a repressor of ATXN7 transcription | 22814587 | LncRNADisease | ||
Spinocerebellar ataxia type 7 | N/A | N/A | N/A | regulation | Genomic context links lncRNAs to disease genes/loci and related pathways | 23791884 | LncRNADisease | ||
Spinocerebellar ataxia type 7 | N/A | N/A | N/A | expression | Long ncRNA SCAANT1 is implicated in a type of polyglutamine disorder, spinocerebellar ataxia type 7 (SCA7). | 24624135 | LncRNADisease | ||
laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | down-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer | ||
Interaction | |||||||||
---|---|---|---|---|---|---|---|---|---|
Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
PARP1 | RNA-Protein | binding | However, it is highly unlikely that the RRP1B-PARP1 interaction is an experimental artifact, since there is loss of binding with the ΔC-term sample. | 19710015 | LncRNADisease | ||||
CSDA | RNA-Protein | binding | Tandem affinity purification demonstrated that RRP1B physically interacts with many nucleosome binding factors, including histone H1X, poly(ADP-ribose) polymerase 1, TRIM28 (tripartite motif-containing 28), and CSDA (cold shock domain protein A). | 19710015 | LncRNADisease | ||||
H1X | RNA-Protein | binding | Tandem affinity purification demonstrated that RRP1B physically interacts with many nucleosome binding factors, including histone H1X, poly(ADP-ribose) polymerase 1, TRIM28 (tripartite motif-containing 28), and CSDA (cold shock domain protein A). | 19710015 | LncRNADisease | ||||
TRIM28 | RNA-Protein | binding | Tandem affinity purification demonstrated that RRP1B physically interacts with many nucleosome binding factors, including histone H1X, poly(ADP-ribose) polymerase 1, TRIM28 (tripartite motif-containing 28), and CSDA (cold shock domain protein A). | 19710015 | LncRNADisease | ||||
Cisplatin and paclitaxel | N/A | regulation | Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | |||||